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ORIGINAL ARTICLE
Digital rectal examination (DRE) is the fundamental 
method of prostate examination in addition to medical his-
tory. DRE is helpful in evaluating prostate volume, which is 
useful in the work-up of prostatitis, benign prostatic hyper-
plasia (BPH) and PC. Evaluation of serum levels of prostate-
specific antigen (PSA) is also useful in the diagnosis of PC. 
PSA has been used for many years during preliminary work-
up of patients over the age of 45 years, and high levels of 
this antigen in the serum form the grounds for further di-
agnostic evaluation. PSA is a proteolytic glycoprotein that 
liquefies semen. It is mainly produced by epithelial cells of 
the prostate and, in much lower quantities, by epithelial 
cells of the seminiferous vesicles, urinary bladder and ure-
thra. The fact that malignant cells are not the only cells that 
produce PSA poses a considerable problem in using it as a 
PC marker. Elevated PSA is also observed in prostatitis and 
BPH. Evaluation of serum PSA is therefore associated with a 
considerable risk of obtaining false results. New, more spe-
cific biomarkers are therefore being looked for extensively 
to replace the currently used PSA in the diagnostic process 
for PC (5-7).
α-Methylacyl-CoA racemase (AMACR) belongs to the 
isomerase family. This enzyme is responsible for convert-
ing R-stereoisomers into S-stereoisomers and is involved in 
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Introduction
Prostate cancer (PC) is the fifth most common cancer 
overall and the second most common cancer in males (1-3). 
In 2008, a total of 900,000 males were diagnosed with PC, 
accounting for 14% of cancers in males and 7% of cancers 
overall. Recent years have seen a considerable increase in 
the incidence of PC in many countries worldwide, with little 
change in PC-related mortality. PC is the sixth most common 
cause of cancer-related deaths in males worldwide. In 2008, 
the number of PC-related deaths was estimated at about 
258,000 (4).
AbSTRACT
background: Because of the numerous limitations of prostate-specific antigen (PSA), α-methylacyl-CoA racemase 
(AMACR) and hepsin have recently been suggested as potential biomarkers in prostate cancer (PC). This report 
presents a comparison study of the presence of AMACR and hepsin in urine collected before and after digital 
rectal examination (DRE) as a previously suggested diagnostic marker for PC.
Methods: Seventy-six urine samples (38 before and 38 after prostate massage) from patients with benign pros-
tate hyperplasia (BPH) and 66 urine samples (33 before and 33 after prostate massage) from patients with PC 
were analyzed. PC was confirmed by prostate biopsy. Urinary levels of AMACR and hepsin were determined by 
ELISA and related to the tumor stage, Gleason score and PSA level.
Results: AMACR and hepsin levels in urine collected after prostate massage were higher only in the PC group. 
There were no correlations between AMACR levels, hepsin levels, tumor stage and Gleason score. AMACR 
and hepsin did not differentiate between BPH and PC with better true positive and false negative rates than 
serum PSA.
Conclusions: AMACR and hepsin were unable to diagnose PC with better true positive and false negative rates 
than PSA. An additional procedure combined with other markers should be applied for the reliable diagnosis 
of PC.
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branched fatty acid beta-oxidation (8, 9). It has been dem-
onstrated that changes in the concentration and activity of 
this enzyme may be associated with various pathologies, 
such as nervous system diseases and tumors (10-12). This 
peroxisomal and mitochondrial enzyme was also found to 
be up-regulated in PC (8, 9). To evaluate the diagnostic ef-
ficacy of AMACR, a total of 96 patients were examined by 
prostate needle biopsy. The AMACR result was positive in 68 
out of 70 patients diagnosed with PC. Sensitivity and speci-
ficity were calculated as 97% and 100%, respectively (8). 
Another study has shown AMACR as a potential biomarker 
with the use of a noninvasive screening test in voided urine. 
The conclusions were based on the determination of AM-
ACR in voided urine specimens collected from 26 men after 
transrectal ultrasound guided prostate biopsy for suspected 
malignancy (13).
The human serine protease hepsin is a cell surface serine 
protease that is markedly up-regulated in human PC. But the 
problem is that the functional significance of this up-regulation 
is still unknown. Overexpression of hepsin in a mouse model of 
PC has no impact on cell proliferation, but causes disorgani-
zation of the basement membrane and promotes primary PC 
progression (14). Hence, hepsin may be regarded as a novel 
potential immunohistochemical marker for the histopathologi-
cal diagnosis of PC (15).
Few studies have been published on the use of AMACR 
and hepsin levels in various biological samples as potential 
markers of PC. We therefore conducted a study to evaluate 
AMACR and hepsin levels and find out whether changes of 
AMAR and hepsin levels in urine before and after prostate 




Urine samples were obtained from patients qualified for 
a surgical procedure in the Department of Urology, Jan Biziel 
University Hospital in Bydgoszcz, Poland. For this study, 2 main 
groups of patients were formed: the cancer group (n = 33) con-
sisted of patients diagnosed with PC admitted to hospital for 
a radical prostatectomy (RP), and the BPH group (n = 38) con-
sisted of patients admitted to the hospital for a transurethral 
resection of the prostate (TURP). Patients selected for the BPH 
group had negative DRE and showed no evidence of malignan-
cy in prostatic tissue collected after TURP. All diagnosis were 
confirmed by histopathological examination of prostate gland 
tissues as part of routine hospital procedures. Prostate volume 
of the glands collected after RP was measured by a patholo-
gist. In the BPH group, it was measured using transrectal ultra-
sound. Because the study sought to determine whether pros-
tate massage has an effect on urine concentrations of AMACR 
and hepsin, only patients that had not had a prostate biopsy 
or other urological procedure in the past 30 day prior admis-
sion to the hospital were asked to participate in this study. Two 
urine samples were collected from each patient. First urine 
sample was collected in the early morning hours in a sterile 
urine container. The second sample was collected after pros-
tate massage performed by the urologist. Prostate massage 
was performed by sweeping each lobe 3 times, depressing the 
prostate gland (0.5-1 cm) in a milking action. All samples were 
prepared for storage immediately after collection. Sodium 
azide solution was added to urine with final concentration of 1 
mM in urine. Then samples were divided into smaller portions, 
stored at -80°C and kept in those conditions until further analy-
sis. All actions regarding diagnostics were conducted accord-
ing to the “Guidelines on the Management of Non-Neurogenic 
Male Lower Urinary Tract Symptoms (LUTS), Including Benign 
Prostatic Obstruction (BPO),” by the European Association of 
Urology. 
Determination of human AMACR and hepsin
For determining AMACR and hepsin levels, 2 separate 
ELISA kits were used. The Human AMACR ELISA Kit (EIAab 
Human Alpha-methylacyl-CoA racemase, Catalog No. 
E0993h; EIAab) Wuhan, China and the Human Serine Prote-
ase Hepsine Elisa Kit (EIAab Human Serine protease hepsin, 
Catalog No. E1856h; EIAab) were used for determination of 
AMACR and hepsin in urine. Wuhan, China Ninety-six well 
plates of immunoassay kit were precoated with an antibody 
specific to each protein. All samples and standards were 
transferred to the wells with a biotin-conjugated polyclonal 
antibody specific to AMACR and human serine protease hep-
sin. The pretreatment of samples and measurements were 
performed following the protocol provided by EIAab. Spec-
trophotometric measurements were performed by micro-
plate reader set to 450 nm. Serial dilutions were prepared 
from a 100 ng/mL stock solution; the standard curve range 
was from 1.56 to 100 ng/mL for AMACR and from 0.78 to 
10 ng/mL for hepsin.
Statistical analysis
Statistical analysis and graphical presentation of results 
were performed using Statistica, version 10 (StatSoft, Tulsa, OK, 
USA) with the medical analyses package. The Mann-Whitney 
test was used for between-group comparisons. For statisti-
cal purposes, patients diagnosed with PC were stratified by 
Gleason score (scores 5-7) and by stage (pT2a, pT2b, pT2c). 
The diagnostic potential of AMACR, hepsin and PSA was deter-
mined using receiver operating characteristic (ROC) curves.
Ethical approval and signed consent
The study was approved by the local ethics committee 
(Collegium Medicum Ethics Committee, #KB66/2011). All pa-
tients signed documents regarding their voluntary participa-
tion in this study. Sample collection was performed between 
January and June 2011.
Results
A total of 66 urine samples from patients with PC and 
76 from patients with BPH were analyzed. Table I presents the 
characteristics of the study population, including the num-
bers of patients, age, serum PSA levels, tumor volume and 
AMACR and hepsin levels before and after prostate massage. 
Both study groups were characterized by a similar age: mean 
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age was 62 and 65 years in the PC and BPH groups, respec-
tively. Regarding the tumor state, the PC group consisted of 
8 patients with pT2a tumors, 5 patients with pT2b tumors and 
20 patients with pT2c tumors. The patients were also strati-
fied by Gleason score: there were 8, 13 and 12 patients with 
a Gleason score of 5, 6 and 7, respectively. The mean and me-
dian serum PSA levels were lower in BPH patients than in PC 
patients. Serum PSA levels in the BPH group were <4 ng/mL 
in 22 patients, 4-10 ng/mL in 15 patients and >10 ng/mL in 
1 patient. Serum PSA levels in the PC group were <4 ng/mL 
in 3 patients, 4-10 ng/mL in 26 patients and >10 ng/mL in 
4 patients.
Alpha-methylacyl-CoA racemase
The lowest AMACR level possible to be measured in the 
sample was 1.56 ng/mL, which resulted from the assay limi-
tation. AMACR levels were below this value in 13 samples 
collected before prostate massage in the BPH group. In the 
PC group, 8 patients had AMACR levels below 1.56 ng/mL. 
AMACR levels below the limit of quantitation were present 
in 22 samples collected after prostate massage in the BPH 
group. In the PC group, again, 8 patients had AMACR levels 
below 1.56 ng/mL. A comparison of the samples collected 
before prostate massage between the BPH and the PC groups 
did not show any statistically significant differences. When 
these 2 groups were compared in terms of AMACR levels af-
ter prostate massage, these levels were significantly higher 
in the PC group (p<0.0001) (Fig. 1). To obtain more detailed 
data, the PC group was stratified by Gleason score. Median 
AMACR levels were 16.57, 26.32 and 55.12 before prostate 
massage and 23.81, 24.68 and 108.37 after massage in pa-
tients with a Gleason score of 5, 6 and 7, respectively. It was 
observed that only when comparing samples after prostate 
massage in patients with a Gleason score of 7 were the lev-
els of AMACR significantly higher than those in patients with 
a Gleason score of 6 (p = 0.038) (Fig. 2). Patients were also 
stratified by tumor stage. Median AMACR levels were 19.65, 
92.55 and 15.15 before prostate massage and 15.3, 113.32 
and 41.63 after prostate massage in patients with pT2a, pT2b 
and pT2c tumors, respectively. No statistically significant dif-
ferences were observed (p>0.05) (Fig. 3). A ROC analysis was 
performed to compare the diagnostic potential of AMACR 
versus PSA. At the cutoff point of 11.7 ng/mL for AMACR lev-
els, true positive and false negative rates were 75% and 26%, 
respectively (area under the curve [AUC] = 0.748; 95% confi-
dence interval [95% CI], 0.63-0.865) (Fig. 4). For comparison, 
a ROC curve for serum PSA levels was also constructed. The 
true positive and false negative rates for the cutoff point of 
4.01 ng/mL were 91% and 39%, respectively (AUC = 0.769; 
95% CI, 0.659-0.879) (Fig. 4).
Human serine protease
The lowest hepsin level possible to be measured in the 
sample was 0.78 ng/mL, which resulted from the assay limita-
tion. Hepsin levels were below this value in 12 samples collect-
ed before prostate massage in the BPH group. In the PC group, 
11 patients had hepsin levels below 0.78 ng/mL. Hepsin levels 
below the limit of quantitation were present in 15 samples 
collected after prostate massage in the BPH group. In the PC 
group, again, 9 patients had hepsin levels below 0.78 ng/mL. 
A comparison of the samples collected before prostate mas-
sage between the BPH and the PC groups did not show any 
statistically significant differences. When these 2 groups were 
compared in terms of hepsin levels after prostate massage, 
these levels were significantly higher in the PC group (p<0.024) 
(Fig. 5). As was the case with the analysis of AMACR levels, 
to obtain more detailed data on urinary hepsin levels, the pa-
tients were stratified by Gleason score (Fig. 6). Median hepsin 
levels were 0.00, 2.42 and 3.30 before prostate massage and 
2.25, 2.41 and 3.10 after massage in patients with a Gleason 
score of 5, 6 and 7, respectively, although no statistically signif-
icant differences were observed. Patients were also stratified 
by tumor stage. Median hepsin levels were 0.00, 3.49 and 2.71 
before prostate massage and 2.66, 1.14 and 2.67 after prostate 
massage in patients with pT2a, pT2b and pT2c tumors, respec-
tively. No statistically significant differences were observed 
TAbLE I - Characteristics of study population
benign Cancer
Number of patients 38 33




Median serum PSA, ng/mL 3.47 6.33






Tumor volume, cm3 (range) - 28.17  
(2.50-90.00)
Mean AMACR level in urine 






Median AMACR level in urine 
collected before prostate 
massage, ng/mL
18.15 23.25
Mean AMACR levels in urine 






Median AMACR level in urine 
collected after prostate  
massage, ng/mL
0.00 44.63
Mean hepsin level in urine 






Median hepsin level in urine 
collected before prostate 
massage, ng/mL
1.77 3.1
Mean hepsin levels in urine 






Median hepsin level in urine 
collected after prostate  
massage, ng/mL
1.14 2.26
AMACR = α-methylacyl-CoA racemase; PSA = prostate-specific antigen.
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Fig. 1 - Group comparison of 
α-methylacyl-CoA racemase (AM-
ACR) concentrations in urine before 
and after prostate massage.
Fig. 2 - Comparison of α-methylacyl-
CoA racemase (AMACR) levels in 
urine collected before after prostate 
massage in cancer patients with dif-
ferent Gleason scores.
Fig. 3 - Comparison of α-methylacyl-
CoA racemase (AMACR) levels in 
urine collected before and after 
prostate massage in cancer patients 
with different tumor stages.
Fig. 4 - Comparison of diagnostic potential of serum prostate-specific antigen (PSA), α-methylacyl-CoA racemase (AMACR) and hepsin using 
ROC curve. AUC = area under the curve.
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(p>0.05) (Fig. 7). An ROC analysis was performed to compare 
the true positive and false negative rates. At the cutoff point 
of 2.25 ng/mL for hepsin levels, the true positive and false 
negative rates were 61% and 25%, respectively (AUC = 0.662; 
95% CI, 0.526-0.798) (Fig. 4).
Discussion
The aim of the study was to establish whether changes 
in urinary levels of selected proteins may be used for dif-
ferentiating between BPH and PC. We decided to compare 
these 2 conditions because high serum PSA levels are very 
often observed in patients with BPH, which leads to incorrect 
initial diagnosis and places the patient at risk of being sub-
Fig. 5 - Group comparison of hepsin 
concentrations in urine before and 
after prostate massage.
Fig. 6 - Comparison of hepsin levels 
in urine collected before and after 
prostate massage in cancer patients 
with different Gleason scores.
Fig. 7 - Comparison of hepsin lev-
els in urine collected before after 
prostate massage in cancer patients 
with different tumor stages.
jected to more invasive diagnostic procedures. In our study, 
we utilized urine samples collected from patients diagnosed 
with BPH and patients diagnosed with PC. We showed that 
only in urine collected after prostate massage were there sig-
nificantly higher levels of both AMACR and hepsin in patients 
with PC. We also showed that in the BPH group, AMACR and 
hepsin levels were lower in samples collected before prostate 
massage. Of the 2 proteins, the between-group differences 
were greater for AMACR. Unfortunately, we did not observe 
any correlations between AMACR and hepsin levels in the 
urine collected before and after prostate massage, tumor 
stage and Gleason score. The comparison of the diagnostic 
potential showed that AMACR allowed for differentiation be-
tween PC and BPH with a true positive rate of 75% and a false 
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positive rate of 26%, and hepsin allowed for differentiation 
between PC and BPH with a true positive rate of 61% and 
a false positive rate of 25%. Compared with the results ob-
tained in the analysis of serum PSA levels and evaluation of 
the usefulness of this parameter for differentiating between 
PC and BPH, PSA levels managed to achieve this aim with a 
higher true positive and false negative rates (91% and 39%, 
respectively). While higher levels of AMACR and hepsin may 
be seen in the PC group, a better solution is sticking to the 
current diagnostic methods (i.e., PSA). PSA has the advan-
tage of not requiring prostate massage before the test (pros-
tate massage is indeed contraindicated). This solution is also 
more comfortable for the patient. In conclusion, AMACR and 
hepsin are not appropriate single markers for the correct dif-
ferentiation between BPH and PC. An alternative could be to 
create a screening test that would include multiple param-
eters, including AMACR and/or hepsin.
Conclusion
AMACR and hepsin were unable to diagnose PC with bet-
ter true positive and false negative rates than PSA. Suppos-
edly, an additional procedure combined with other markers 
should be applied for the reliable diagnosis of cancer stage 
and further treatment. A combined, fast and noninvasive 
assay might be of special importance in the screening proce-
dure for elderly men.
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